WINT vs. GMDAQ, ELOX, ALBT, FNCH, SCNI, KRBP, SQZ, TCBP, TCON, and FRTX
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Scinai Immunotherapeutics (SCNI), Kiromic BioPharma (KRBP), SQZ Biotechnologies (SQZ), TC Biopharm (TCBP), TRACON Pharmaceuticals (TCON), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDAQ) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.
Windtree Therapeutics' return on equity of 0.00% beat Gamida Cell's return on equity.
In the previous week, Gamida Cell had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Gamida Cell and 0 mentions for Windtree Therapeutics. Gamida Cell's average media sentiment score of 0.98 beat Windtree Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
Gamida Cell has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Windtree Therapeutics has lower revenue, but higher earnings than Gamida Cell. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Windtree Therapeutics received 3 more outperform votes than Gamida Cell when rated by MarketBeat users.
50.3% of Gamida Cell shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 6.7% of Gamida Cell shares are held by insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Gamida Cell beats Windtree Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
